| Objective:Epithelial Ovarian Cancer(EOC)is a very high mortality gynaecological malignancy.Due to the lack of obvious early symptoms and specific molecular markers,many patients have developed into the advanced stage at the time of diagnosis.The main treatment of EOC is cytoreductive surgery combined with chemotherapy drugs such as paclitaxel and platinum drugs.As the diagnostic and therapeutic techniques develop,the mortality rate is still only slightly improved.The main baffle to medical treatment is drug resistance and metastasis.Therefore,the discovery of specific molecular markers and the mechanism involved in chemoresistance are of great value in reversing chemotherapy resistance of ovarian cancer and reducing the mortality of ovarian cancer,and may become potential targets for EOC treatment.Numerous research reports have reported that mi RNAs can be taken part in tumor chemotherapy resistance.mi R-200b-3p is a important part of the mi R-200 clan and has been reported to be associated with tumor chemoresistance in a variety of tumors,but studies in ovarian cancer have rarely been reported.The goal of this survey is : 1)to research the differential expression of mi R-200b-3P in chemotherapeutic and chemosensitive tissues of ovarian cancer and its relation with Clinical pathological factors;and 2)To explore the involvement of mi R-200b-3P in ovarian cancer.Molecular mechanism.Methods:1.Micro RNA expression profiling revealed that mi R-200b-3p is highly expressed in chemo-resistant tissues of epithelial ovarian cancer compared with chemotherapy-sensitive tissues of epithelial ovarian cancer.Real-time PCR analysis of 25 pairs of epithelial ovarian cancer chemotherapy-resistant tissue/sensitive tissue samples showed that mi R-200b-3p is highly expressed in colon cancer patients.The presentment of mi R-200b-3p in the ovarian cancer patients was extraordinaryly higher than the presentment of mi R-200b-3p in the sensitive group,which was 15.78 times higher than the expression of mi R-200b-3p in the sensitive group.2.By correlating the clinicopathological parameters of mi R-200b-3p with epithelial ovarian cancer patients,the high expression of mi R-200b-3p was associated with clinical pathological stage and lymph node metastasis(P<0.05),and patients' Other clinical pathological parameters were not associated(P<0.05).3.PAK2 may be one of the target genes of mi R-200b-3p.The expression of PAK2 m RNA in the ovarian cancer patients of the drug-resistant group is significantly lower than that of the sensitive group,that is 0.03 times that of the sensitive group,and the expression of PAK2 m RNA in ovarian cancer which is negatively correlated with the expression of mi R-200b-3p.the expression of PAK2 m RNA is declined with the increase of mi R-200b-3p expression.Results:1.mi R-200b-3p is highly expressed in chemo-resistant epithelial ovarian cancer.The high expression of mi R-200b-3p was associated with clinical pathological stage and lymph node metastasis in patients with epithelial ovarian cancer,and(P<0.05),and was unrelated with other clinical pathology factors(P<0.05).2.mi R-200b-3p over-expressed in chemotherapy-resistant ovarian cancer,might be one through the targeted regulation of PAK2 m RNA participated in the regulation of chemotherapy resistance and accelerate ovarian cancer metastasis.Conclusion:1.mi R-200b-3p is highly expressed in chemotherapy-resistant ovarian cancer.2.The high expression of mi R-200b-3p was associated with the clinical pathological stage of patients with epithelial ovarian cancer.The results were statistically significant,but were not related to the remaining clinicopathological parameters of the patients.The results were statistically significant.3.mi R-200b-3p may be involved in the regulation of chemoresistance and ovarian cancer metastasis by targeting PAK2 m RNA. |
PDF Full Text Request